N4 Pharma Plc Regulatory News (N4P)

24 September 2018

N4 Pharma Plc

("N4 Pharma" or the "Company")

Acceptance of Nuvec® on EUNCL Charecterisation programme

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company, today announces that it has been accepted by the European Nanomedicine Charecterisation Laboratory ("EUNCL") to undertake a full charecterisation program for the Company's Nuvec® delivery system.

The EUNCL is a European network of institutions funded by Horizon 2020, (Grant Agreement Number 654190) an €5M fund to accelerate the development of promising nanotech therapies and diagnostics. Based on this expertise the EUNCL developed an "assay cascade" for new nanomaterials which covers the physical and chemical characterisation ("PCC") as well as in vitro and in vivo biological properties of nanomaterials. This set of assays will allow a full characterisation of Nuvec®.

The aim of EUNCL is to provide state-of-the-art pre-clinical characterisation of innovative nanomaterials such as Nuvec® in order to accelerate their development towards regulatory approval by the European Medicines Agency ("EMA") and the national agencies.

Nigel Theobald, CEO of N4 Pharma commented: 

"The acceptance by EUNCL onto this program is a huge step in the right direction for our Nuvec® development plans. The program will provide us with direct access to leading nanomaterial experts across Europe to allow us to do a full regulatory assessment of Nuvec® and provide invaluable information to our potential collaboration partners.

"The acceptance by EUNCL is a strong indication of the exciting potential for our Nuvec® system and as the costs of these studies will be met within the EUNCL grant, it significantly reduces the cost to the Company of our regulatory development program."

Enquiries: